West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. Asian Pacific Journal of Cancer Prevention 1513-7368 19 5 2018 05 01 Therapeutic Use of Metformin in Diabetes and Survival Outcomes in Endometrial Cancer Patients with Diabetes 1295 1302 60802 10.22034/APJCP.2018.19.5.1295 EN Putsarat Insin Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Rajavithi Hospital, Bangkok, Thailand. College of Medicine, Rangsit University, Bangkok, Thailand. 0000-0003-1894-4125 Nisa Prueksaritanond Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Rajavithi Hospital, Bangkok, Thailand. College of Medicine, Rangsit University, Bangkok, Thailand. Journal Article 2017 10 27 Objectives: To compare survival outcomes between endometrial cancer (EC) patients with diabetes who used<br />metformin to those who did not use metformin. Materials and Methods: A retrospective cohort study was conducted<br />of EC patients who were diabetes at the time of their cancer diagnosis and had been scheduled for elective surgery<br />at Rajavithi Hospital between 1 January 2003 and 31 December 2013. The patients were excluded if they had type<br />I diabetes mellitus and a history of other cancers. Results: Of 1,262 EC patients in the study period, there was 212<br />(16.8%) patients who met the inclusion criteria. Among them, 90 (42.5%) were non-metformin users and 122 (57.5%)<br />were metformin users. With a median follow-up of 47 months, the 5-year overall survivals (76.4% vs 77.9%, p=0.959)<br />and the 5-year progression-free survivals (92.6% vs 84.7%, p=0.091) did not significantly differ between the both<br />groups. On Cox proportional-hazards regression analysis, independent prognostic factors for overall survival (OS)<br />were FIGO stage, depth of myometrial invasion, and cervical involvement. Patients with non-endometrioid histology<br />and advanced stage were found to have a significant effect on progression-free survival (PFS). However, metformin<br />used did not predict either OS (HR, 0.99; 95%CI, 0.56-1.73; p=0.959) or PFS (HR, 2.19; 95%CI, 0.86-5.55; p=0.099).<br />Conclusion: Overall, a significant effect of metformin on survival outcomes in EC patients with diabetes was not found<br />in the current study. Larger studies with a prospective randomized control design are needed to clarify the benefit of<br />metformin as a strategy for endometrial cancer prevention and treatment. https://journal.waocp.org/article_60802_6d01ad7e13a463465c96dfccca60ebd1.pdf